PA-PCI-PHARMA-SERVICES
27.7.2022 10:02:09 CEST | Business Wire | Press release
PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced a significant expansion of its world-class facility in Tredegar, Wales, UK, designed to help keep pace with the market growth of powerful, targeted oncology therapies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220727005014/en/
“We’re excited to announce the latest expansion in Tredegar that will address the growing and urgent need for specialty global manufacturing services within the oncology arena,” said Salim Haffar, Chief Executive Officer, PCI Pharma Services. “As the market expands for potent therapies and highly complex, concentrated formulations that can present unique challenges to manufacturing and packaging, we’re proud to be one of the few providers with the global capabilities to manage this specialty at both clinical and importantly, commercial scale.”
The expansion includes two new facilities dedicated to the manufacturing and packaging of solid oral-dose tablets and capsules. A second contained manufacturing building (CMF2), capitalizing on the success of the original CMF1 which opened in 2013, will double large-scale processing capacity including dispensing and fluid bed granulation of high-potency solid-dose products at the commercial scale. In addition, there is a new high-potency, multi-product packaging facility with primary and secondary blistering and bottling suites. The primary and secondary packaging lines provide a fully integrated process, delivering end-to-end services for a global client base.
More than 1,300 medicines and vaccines in clinical trials were indicated for cancer treatment in 2021, compared to 1,100 two years prior. Oncology treatments also accounted for 25% of all medicines approved by the FDA between 2010 and 2019, signaling that oncology will remain a key focus for the industry in the upcoming years.
“The rapid evolution of oncology pipelines has coincided with the continued globalization of clinical development,” said Rebecca Coutts, Ph.D., General Manager, Tredegar, PCI Pharma Services. “This latest investment, along with the existing analytical and formulation capabilities, combines a clinical and c ommercial scale packaging facility to complement the existing clinical and increased commercial scale manufacturing capabilities, placing end-to-end services for these high-potency molecules under one roof to better serve our client’s evolving needs.”
Both facilities will contain state-of-the-art equipment, including a replica of CMF1’s large-scale granulation suite and a down-flow booth with containment screening. Duplicating the original state-of-the-art CMF1 facility will provide both greater capacity and business continuity for clients.
The Tredegar expansion is also expected to create up to 40 new jobs in the first year and add more as the facilities scale up. PCI Tredegar currently employs close to 500 people, almost doubling the number of employees since the opening of CMF1 in 2013. PCI has been operating in Tredegar UK for nearly 40 years and is one of the most significant employers in the local area. For more information on PCI’s high potent development and manufacturing capabilities, please click here .
About PCI Pharma Services
PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain) and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220727005014/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom